Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1, 5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition. (1st July 2021)

• Record Type: Journal Article
• Authors: Akiu, Mayuko; Tsuji, Takashi; Sogawa, Yoshitaka; Terayama, Koji; Yokoyama, Mika; Tanaka, Jun; Asano, Daigo; Sakurai, Ken; Sergienko, Eduard; Sessions, E. Hampton; Gardell, Stephen J.; Pinkerton, Anthony B.; Nakamura, Tsuyoshi
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 43(2021)
• Publication Date: 2021-07-01
• Subjects: NAMPT activators -- NAD+ -- Triazolopyridines -- CYP inhibition -- LogD; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2021.128048
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of the NAD + salvage pathway. Since NAD + plays a pivotal role in many biological processes including metabolism and aging, activation of NAMPT is an attractive therapeutic target for treatment of diverse array of diseases. Herein, we report the continued optimization of novel urea-containing derivatives which were identified as potent NAMPT activators. Early optimization of HTS hits afforded compound 12, with a triazolopyridine core, as a lead compound. CYP direct inhibition (DI) was identified as an issue of concern, and was resolved through modulation of lipophilicity to culminate in 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1, 2, 4]triazolo[1, 5- a ]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea (21 ), which showed potent NAMPT activity accompanied with attenuated CYP DI towards multiple CYP isoforms.